COGT
Cogent Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$34.67
−0.80%Next report
Analyst consensus
- Next report date
- Nov 6, 2026
- EPS estimate
- -$0.57
- Revenue estimate
- $750.0K
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.52
- EPS estimate
- -$0.55
- Revenue actual
- —
- Revenue estimate
- $1.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +1.5%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $54
- PT range
- $52 – $55
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 6, 2026